Literature DB >> 11573866

Treatment of attention deficit hyperactivity disorder in children.

W A Kehoe.   

Abstract

These are controversial times for those who care for children with attention deficit hyperactivity disorder (ADHD). Class action law suits have been filed in federal courts in California and New Jersey accusing a manufacturer of methylphenidate and the American Psychiatric Association of conspiring to expand the use of this drug. These suits have recently been dismissed. This is just the latest chapter in the long-running debate over the existence, diagnosis, and treatment of ADHD. Controversies relating to ADHD continue to polarize physicians, educators, caregivers, and parents of these children. There are those who believe that ADHD does not exist as a true disorder. At the other end of the spectrum are those who are too quick to make the diagnosis without an adequate patient workup. Parents can unfortunately get caught in the middle of this debate when making treatment decisions for their children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573866     DOI: 10.1345/aph.10353

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  4 in total

1.  Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.

Authors:  Rozita Davari-Ashtiani; Mahin Eslami Shahrbabaki; Katayoon Razjouyan; Homayoun Amini; Homa Mazhabdar
Journal:  Child Psychiatry Hum Dev       Date:  2010-12

2.  Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder.

Authors:  Fariba Arabgol; Leily Panaghi; Paria Hebrani
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-06-18       Impact factor: 4.785

3.  Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].

Authors:  Shahin Akhondzadeh; Mohammad-Reza Mohammadi; Mojgan Khademi
Journal:  BMC Psychiatry       Date:  2004-04-08       Impact factor: 3.630

4.  Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial.

Authors:  Mohammad Reza Mohammadi; Soleiman Mohammadzadeh; Shahin Akhondzadeh
Journal:  Iran J Psychiatry       Date:  2015-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.